Identification of antiviral compounds against equid herpesvirus‐1 using Real‐Time Cell Analysis: screening of 2,891 molecules (original) (raw)

Abstract

Equid herpesvirus-1 infections cause respiratory, neurological and reproductive syndromes. Despite preventive treatments with vaccines, resurgence of EHV-1 infection still constitutes a major threat to equine industry. However, no antiviral compound is available to treat infected horses. In this study, 2891 compounds were screened against EHV-1 using impedance measurement. 22 compounds have been found to be effective in vitro against EHV-1. Valganciclovir, ganciclovir, decitabine, aphidicolin, idoxuridine and pritelivir (BAY 57-1293) are the most effective compounds identified, and their antiviral potency was further assessed on E. Derm, RK13 and EEK cells and against 3 different field strains of EHV-1 (ORF30 2254 A/G/C). We also provide evidences of synergistic interactions between valganciclovir and decitabine in our in vitro antiviral assay as determined by MacSynergy II, isobologramm and Chou-Talalay methods. Finally, we showed that deoxycytidine reverts the antiviral effect of decitabine, thus supporting some competition at the level of nucleoside phosphorylation by deoxycytidine kinase and/or DNA synthesis. Deoxycitidine analogues, like decitabine, is a family of compounds identified for the first time with promising antiviral efficacy against herpesviruses.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (58)

  1. Allen, G.P., Kydd, J.H., Slater, J.D., Smith, K.C., 2004. Equid herpesvirus-1 (EHV-1) and -4 -EHV-4) infectious. In: Coetzer, J.A.W., Tustin, R.C. (Eds.), Infectious Diseases of Livestock, 2nd edn. Oxford Press, Cape Town, pp. 829-859.
  2. Atallah, E., Kantarjian, H., Garcia-Manero, G., 2007. The role of decitabine in the treatment of myelodysplastic syndromes. Expet Opin. Pharmacother. 8, 65-73. https://doi.org/10.1517/14656566.8.1.65.
  3. Azab, W., Tsujimura, K., Kato, K., Arii, J., Morimoto, T., Kawaguchi, Y., Tohya, Y., Matsumura, T., Akashi, H., 2010. Characterization of a thymidine kinase-deficient mutant of equine herpesvirus 4 and in vitro susceptibility of the virus to antiviral agents. Antivir. Res. 85, 389-395. https://doi.org/10.1016/j.antiviral.2009.11.007.
  4. Berg, T., Nøttrup, T.J., Roed, H., 2019. Gemcitabine for recurrent ovarian cancer -a systematic review and meta-analysis. Gynecol. Oncol. 155, 530-537. https://doi. org/10.1016/j.ygyno.2019.09.026.
  5. Betz, U.A.K., Fischer, R., Kleymann, G., Hendrix, M., Rubsamen-Waigmann, H., 2002. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob. Agents Chemother. 46, 1766-1772. https://doi. org/10.1128/AAC.46.6.1766-1772.2002.
  6. Carmichael, R.J., Whitfield, C., Maxwell, L.K., 2013. Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. J. Vet. Pharmacol. Therapeut. 36, 441-449. https://doi.org/10.1111/jvp.12029.
  7. Chou, T.-C., Talalay, P., 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 22, 27-55. https://doi.org/10.1016/0065-2571(84)90007-4.
  8. De Clercq, E., 1984. The antiviral spectrum of (£)-5-(2-bromovinyl)-2 '-deoxyuridine. J. Antimicrob. Chemother. 14, 85-95.
  9. De Clercq, E., Li, G., 2016. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695-747. https://doi.org/10.1128/CMR.00102-15.
  10. de la Fuente, R., Awan, A.R., Field, H.J., 1992. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antivir. Res. 18, 77-89.
  11. Denisova, O.V., Kakkola, L., Feng, L., Stenman, J., Nagaraj, A., Lampe, J., Yadav, B., Aittokallio, T., Kaukinen, P., Ahola, T., Kuivanen, S., Vapalahti, O., Kantele, A., Tynell, J., Julkunen, I., Kallio-Kokko, H., Paavilainen, H., Hukkanen, V., Elliott, R. M., De Brabander, J.K., Saelens, X., Kainov, D.E., 2012. Obatoclax, Saliphenylhalamide, and gemcitabine inhibit Influenza A virus infection. J. Biol. Chem. 287, 35324-35332.
  12. Drouot, E., Piret, J., Boivin, G., 2016. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir. Ther. 21, 535-539. https://doi.org/10.3851/IMP3028.
  13. Fang, Y., Ye, P., Wang, X., Xu, X., Reisen, W., 2011. Real-time monitoring of flavivirus induced cytopathogenesis using cell electric impedance technology. J. Virol. Methods 173, 251-258. https://doi.org/10.1016/j.jviromet.2011.02.013.
  14. Feng, J.Y., Ly, J.K., Myrick, F., Goodman, D., White, K.L., Svarovskaia, E.S., Borroto- Esoda, K., Miller, M.D., 2009. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6, 44. https://doi.org/10.1186/1742-4690-6-44.
  15. Ferreira, C.G.T., Campos, M.G., Felix, D.M., Santos, M.R., Carvalho, O.V. de, Diaz, M.A. N., Fietto, J.L.R., Bressan, G.C., Silva-Júnior, A., Almeida, M.R. de, 2018. Evaluation of the antiviral activities of Bacharis dracunculifolia and quercetin on Equid herpesvirus 1 in a murine model. Res. Vet. Sci. 120, 70-77. https://doi.org/ 10.1016/j.rvsc.2018.09.001.
  16. Friday, P.A., Scarratt, W.K., Elvinger, F., Timoney, P.J., Bonda, A., 2000. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses. J. Vet. Intern. Med. 14, 197-201.
  17. Garre, B., Gryspeerdt, A., Croubels, S., De Backer, P., Nauwynck, H., 2009. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Vet. Microbiol. 135, 214-221. https://doi.org/10.1016/j.vetmic.2008.09.062.
  18. Garre, B., Vandermeulen, K., Nugent, J., Neyts, J., Croubels, S., Debacker, P., Nauwynck, H., 2007. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet. Microbiol. 122, 43-51. https://doi.org/10.1016/j.vetmic.2007.01.004.
  19. Gibson, J.S., 1992. The activity of (S)-l-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses. Antivir. Res. 19, 219-232.
  20. Glorieux, S., Vandekerckhove, A.P., Goris, N., Yang, X.-Y., Steukers, L., Van de Walle, G. R., Croubels, S., Neyts, J., Nauwynck, H.J., 2012. Evaluation of the antiviral activity of (1 ′ S,2 ′ R)-9-[[1 ′ ,2 ′ -bis(hydroxymethyl)cycloprop-1 ′ -yl]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants. Antivir. Res. 93, 234-238. https://doi.org/10.1016/j. antiviral.2011.11.016.
  21. Goodman, L.B., Loregian, A., Perkins, G.A., Nugent, J., Buckles, E.L., Mercorelli, B., Kydd, J.H., Palù, G., Smith, K.C., Osterrieder, N., Davis-Poynter, N., 2007. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog. 3, e160. https://doi.org/10.1371/journal.ppat.0030160.
  22. Gravina, H.D., Tafuri, N.F., Silva Júnior, A., Fietto, J.L.R., Oliveira, T.T., Diaz, M.A.N., Almeida, M.R., 2011. In vitro assessment of the antiviral potential of trans-cinnamic acid, quercetin and morin against equid herpesvirus 1. Res. Vet. Sci. 91, e158-e162. https://doi.org/10.1016/j.rvsc.2010.11.010.
  23. Halbrook, C.J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., Hong, H.S., Kremer, D.M., Nelson, B.S., Kemp, S., Zhang, L., Chang, D., Biankin, A., Shi, J., Frankel, T.L., Crawford, H.C., Morton, J.P., Pasca di Magliano, M., Lyssiotis, C.A., 2019. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabol. 29, 1390-1399. https://doi.org/10.1016/j.cmet.2019.02.001 e6.
  24. He, P.-F., Zhou, J.-D., Yao, D.-M., Ma, J.-C., Wen, X.-M., Zhang, Z.-H., Lian, X.-Y., Xu, Z.- J., Qian, J., Lin, J., 2017. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget 8, 41498-41507. https://doi.org/10.18632/oncotarget.17241.
  25. Henninger, R.W., Reed, S.M., Saville, W.J., Allen, G.P., Hass, G.F., Kohn, C.W., Sofaly, C., 2007. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university Equestrian center. J. Vet. Intern. Med. 21, 157-165.
  26. James, S., Larson, K., Acosta, E., Prichard, M., 2015. Helicase-primase as a target of new therapies for herpes simplex virus infections. Clin. Pharmacol. Ther. 97, 66-78. https://doi.org/10.1002/cpt.3.
  27. Jiang, Y.-C., Feng, H., Lin, Y.-C., Guo, X.-R., 2016. New strategies against drug resistance to herpes simplex virus. Int. J. Oral Sci. 8, 1-6.
  28. Jourdan, J., Bureau, R., Rochais, C., Dallemagne, P., 2020. Drug repositioning: a brief overview. J. Pharm. Pharmacol. jphp. 13273 https://doi.org/10.1111/jphp.13273.
  29. Kit, S., Ichimura, H., De Clercq, E., 1987. Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinase. Antivir. Res. 7, 53-67. https://doi.org/10.1016/0166-3542(87)90039-8.
  30. Kleymann, G., Fischer, R., Betz, U.A.K., Hendrix, M., Bender, W., Schneider, U., Handke, G., Eckenberg, P., Hewlett, G., Pevzner, V., Baumeister, J., Weber, O., Henninger, K., Keldenich, J., Jensen, A., Kolb, J., Bach, U., Popp, A., Mäben, J., Frappa, I., Haebich, D., Lockhoff, O., Rübsamen-Waigmann, H., 2002. New helicase- primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8, 392-398. https://doi.org/10.1038/nm0402-392.
  31. Léon, A., Fortier, G., Fortier, C., Freymuth, F., Tapprest, J., Leclercq, R., Pronost, S., 2008. Detection of equine herpesviruses in aborted foetuses by consensus PCR. Vet. Microbiol. 126, 20-29. https://doi.org/10.1016/j.vetmic.2007.06.019.
  32. Liu, Z., Liu, S., Xie, Z., Blum, W., Perrotti, D., Paschka, P., Klisovic, R., Byrd, J., Chan, K. K., Marcucci, G., 2007. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC- MS/MS method. Nucleic Acids Res. 35 https://doi.org/10.1093/nar/gkl1156 e31-e31.
  33. Lunn, D.P., Davis-Poynter, N., Flaminio, M.J.B.F., Horohov, D.W., Osterrieder, K., Pusterla, N., Townsend, H.G.G., 2009. Equine herpesvirus-1 consensus statement. J. Vet. Intern. Med. 23, 450-461. https://doi.org/10.1111/j.1939-1676.2009.0304\. x.
  34. Maggs, D.J., Clarke, H.E., 2004. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am. J. Vet. Res. 65, 399-403. https://doi.org/10.2460/ajvr.2004.65.399.
  35. Maxwell, L.K., 2017. Antiherpetic drugs in equine medicine. Vet. Clin. N. Am. Equine Pract. 33, 99-125. https://doi.org/10.1016/j.cveq.2016.12.002.
  36. Maxwell, L.K., Bentz, B.G., Bourne, D.W.A., Erkert, R.S., 2008. Pharmacokinetics of valacyclovir in the adult horse. J. Vet. Pharmacol. Therapeut. 31, 312-320. https:// doi.org/10.1111/j.1365-2885.2008.00957.x.
  37. Momparler, R.L., 2005. Pharmacology of 5-Aza-2 ′ -deoxycytidine (decitabine). Semin. Hematol. 42, S9-S16. https://doi.org/10.1053/j.seminhematol.2005.05.002.
  38. Murray, M.J., Piero, F., Jeffrey, S.C., Davis, M.S., Furr, M.O., Dubovi, E.J., Mayo, J.A., 1998. Neonatal equine herpesvirus type 1 infection on a thoroughbred breeding farm. J. Vet. Intern. Med. 12, 36-41. https://doi.org/10.1111/j.1939-1676.1998\. tb00494.x.
  39. Nugent, J., Birch-Machin, I., Smith, K.C., Mumford, J.A., Swann, Z., Newton, J.R., Bowden, R.J., Allen, G.P., Davis-Poynter, N., 2006. Analysis of equid herpesvirus 1 strain variation reveals a point mutation of the DNA polymerase strongly associated with neuropathogenic versus nonneuropathogenic disease outbreaks. J. Virol. 80, 4047-4060. https://doi.org/10.1128/JVI.80.8.4047-4060.2006.
  40. Paillot, R., Sutton, G., Thieulent, C., Marcillaud-Pitel, C., Pronost, S., 2020. New EHV-1 variant identified. Vet. Rec. 186, 573.
  41. Pan, T., Huang, B., Zhang, W., Gabos, S., Huang, D.Y., Devendran, V., 2013. Cytotoxicity assessment based on the AUC50 using multi-concentration time-dependent cellular response curves. Anal. Chim. Acta 764, 44-52. https://doi.org/10.1016/j. aca.2012.12.047.
  42. Piret, J., Goyette, N., Boivin, G., 2016. Novel method based on real-time cell analysis for drug susceptibility testing of herpes simplex virus and human cytomegalovirus. J. Clin. Microbiol. 54, 2120-2127. https://doi.org/10.1128/JCM.03274-15.
  43. Price, N.B., Prichard, M.N., 2011. Progress in the development of new therapies for herpesvirus infections. Curr. Opin. Virol. 1, 548-554. https://doi.org/10.1016/j. coviro.2011.10.015.
  44. Prichard, M.N., Shipman, C., 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14, 181-206.
  45. Pronost, S., Léon, A., Legrand, L., Fortier, C., Miszczak, F., Freymuth, F., Fortier, G., 2010. Neuropathogenic and non-neuropathogenic variants of equine herpesvirus 1 in France. Vet. Microbiol. 145, 329-333. https://doi.org/10.1016/j. vetmic.2010.03.031.
  46. Rollinson, E.A., 1987. Comparative efficacy of three 2 ′ -fluoropyrimidine nucleosides and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (BW B759U) against pseudorabies and equine rhinopneumonitis virus infection in vitro and in laboratory animals. Antivir. Res. 7, 25-33. https://doi.org/10.1016/0166-3542(87)90036-2.
  47. Schmelz, K., Sattler, N., Wagner, M., Lübbert, M., Dörken, B., Tamm, I., 2005. Induction of gene expression by 5-Aza-2 ′ -deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation- dependent and -independent mechanisms. Leukemia 19, 103-111. https://doi.org/ 10.1038/sj.leu.2403552.
  48. Shin, H., Kim, C., Cho, S., 2018. Gemcitabine and nucleos(t)ide synthesis inhibitors are broad-spectrum antiviral drugs that activate innate immunity. Viruses 10, 1-11. https://doi.org/10.3390/v10040211.
  49. Smith, K.L., Allen, G.P., Branscum, A.J., Frank Cook, R., Vickers, M.L., Timoney, P.J., Balasuriya, U.B.R., 2010. The increased prevalence of neuropathogenic strains of EHV-1 in equine abortions. Vet. Microbiol. 141, 5-11. https://doi.org/10.1016/j. vetmic.2009.07.030.
  50. Stresemann, C., Lyko, F., 2008. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Canc. 123, 8-13. https://doi.org/10.1002/ ijc.23607.
  51. Sullivan, V., Talarico, C.L., Stanat, S.C., Davis, M., Coen, D.M., Biron, K.K., 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358, 162-164.
  52. Sutton, Garvey, Cullinane, A., Jourdan, M., Fortier, C., Moreau, P., Foursin, M., Gryspeerdt, A., Maisonnier, V., Marcillaud-Pitel, C., Legrand, L., Paillot, Pronost, 2019. Molecular surveillance of EHV-1 strains circulating in France during and after the major 2009 outbreak in Normandy involving respiratory infection, neurological disorder, and abortion. Viruses 11, 916. https://doi.org/10.3390/v11100916.
  53. Tallmadge, R.L., Žygelyt ė, E., Van de Walle, G.R., Kristie, T.M., Felippe, M.J.B., 2018. Effect of a histone demethylase inhibitor on equine herpesvirus-1 activity in vitro. Front. Vet. Sci. 5 https://doi.org/10.3389/fvets.2018.00034.
  54. Thieulent, C.J., Hue, E.S., Fortier, C.I., Dallemagne, P., Zientara, S., Munier-Lehmann, H., Hans, A., Fortier, G.D., Pitel, P.-H., Vidalain, P.-O., Pronost, S.L., 2019. Screening and evaluation of antiviral compounds against Equid alpha-herpesviruses using an impedance-based cellular assay. Virology 526, 105-116. https://doi.org/10.1016/j. virol.2018.10.013.
  55. Vissani, M.A., Thiry, E., Dal Pozzo, F., Barrandeguy, M., 2016. Antiviral agents against equid alphaherpesviruses: current status and perspectives. Vet. J. 207, 38-44. https://doi.org/10.1016/j.tvjl.2015.06.010.
  56. Wang, J., Li, A., Jin, M., Zhang, F., Li, X., 2016. Dual-modality imaging demonstrates the enhanced antitumoral effect of herpes simplex virus-thymidine kinase/ganciclovir plus gemcitabine combination therapy on cholangiocarcinoma. Experimental and Therapeutic Medicine 12, 183-189. https://doi.org/10.3892/etm.2016.3294.
  57. Williams, S.L., Hartline, C.B., Kushner, N.L., Harden, E.A., Bidanset, D.J., Drach, J.C., Townsend, L.B., Underwood, M.R., Biron, K.K., Kern, E.R., 2003. In vitro activities of benzimidazole D-and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47, 2186-2192. https://doi.org/10.1128/AAC.47.7.2186-2192.2003.
  58. Zhang, J.-H., Chung, T.D.Y., Oldenburg Kevin, R., 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4, 67-73.